Large-scale production of pharmaceutical proteins in plant cell culture-the protalix experience

146Citations
Citations of this article
285Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Protalix Biotherapeutics develops recombinant human proteins and produces them in plant cell culture. Taliglucerase alfa has been the first biotherapeutic expressed in plant cells to be approved by regulatory authorities around the world. Other therapeutic proteins are being developed and are currently at various stages of the pipeline. This review summarizes the major milestones reached by Protalix Biotherapeutics to enable the development of these biotherapeutics, including platform establishment, cell line selection, manufacturing process and good manufacturing practice principles to consider for the process. Examples of the various products currently being developed are also presented.

Cite

CITATION STYLE

APA

Tekoah, Y., Shulman, A., Kizhner, T., Ruderfer, I., Fux, L., Nataf, Y., … Shaaltiel, Y. (2015, October 1). Large-scale production of pharmaceutical proteins in plant cell culture-the protalix experience. Plant Biotechnology Journal. https://doi.org/10.1111/pbi.12428

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free